• Educational resources
  • Events
  • Expert Panel
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MalaysiaChange country/region
Type 2 Inflammation

American Academy of Allergy, Asthma, & Immunology (AAAAI) 2023 | San Antonio

Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.
Theresa Guilbert
Fred  Ghali
Jonathan Spergel
MD, MS
Theresa Guilbert +2 more
EventsOnDemand AAAAI2023
Past event
25February2023
Location
San Antonio, TX USA

Learning objectives

  • Examine interconnectivity between type 2 inflammation, barrier disruption, and clinical consequences of type 2 inflammatory diseases such as atopic dermatitis, asthma, and EoE
  • Understand onset and persistence of type 2 inflammation, and potential disease trajectories of atopic dermatitis, asthma, and EoE in pediatric patients

Description

  • Pediatric Type 2 Inflammatory Disease Progression
    • Global experts Drs. Theresa Guilbert, Fred Ghali, and Jonathan Spergel discuss the role of type 2 inflammation in atopic dermatitis, asthma, and eosinophilic esophagitis in pediatric patients.

Location

San Antonio, TX USA
Tags
pediatricbarrier dysfunctiondisease progressionsymptomsquality of lifemicrobiometissue remodelingtype 2 inflammation
MAT-GLB-2300884 - 1.0 - 03/2023

Speakers

Pulmonology
MD, MS

Theresa Guilbert

Professor | University of Cincinnati; Director of the Asthma Center | Cincinnati Children’s Hospital Medical Center, Ohio, United States

Dermatology
MD

Fred Ghali

Adjunct Associate Professor of Dermatology | University of Texas Southwestern Medical School and Baylor Medical Department of Dermatology, Dallas, United States

Allergy/Immunology
MD, PhD

Jonathan Spergel

Professor of Pediatrics | Perelman School of Medicine, University of Pennsylvania; Chief of Allergy Section and Director of the Center for Pediatric Eosinophilic Disorders | Children’s Hospital of Philadelphia, Pennsylvania, United States